Remix Therapeutics, an RNA-focused company launched over a year ago developing its REMaster drug discovery platform, has entered a strategic small molecule discovery and development collaboration with Janssen Pharmaceutica N.V., a division of Johnson & Johnson.   The collaboration leverages Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing. While the collaboration details have not been disclosed, Janssen will have exclusive...